Zacks Investment Research downgraded shares of Hill-Rom Holdings Inc (NYSE:HRC) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Over the last three months, Hill-Rom is trading above the broader Medical Product industry. Management is currently looking to gain traction in the untapped international market with its efficient international team and organizational realignment. The company also continues to grow on its strategy of product expansion and diversification with recent launch of its surgical beds. We are also looking forward to the company's plan to divest its non-profitable Volker business to focus more on its core arms. Geographically, over the recent past, Hill-Rom consistently posted strong growth in the U.S. and also delivered a solid gross margin. Management’s outlook for 2017 also raises optimism. However, the company has faced difficulties in the Asia-Pacific region of late. Also, with more than 30% sales generating outside, Hill-Rom faces hitch related to adverse currency fluctuations. The highly competitive market is a major concern.”
Several other analysts have also recently issued reports on HRC. Barclays PLC increased their target price on shares of Hill-Rom Holdings from $70.00 to $75.00 and gave the stock an overweight rating in a research note on Wednesday, April 19th. Stifel Nicolaus increased their target price on shares of Hill-Rom Holdings from $70.00 to $84.00 and gave the stock a buy rating in a research note on Monday, May 1st. ValuEngine upgraded shares of Hill-Rom Holdings from a hold rating to a buy rating in a research note on Friday, June 2nd. Cantor Fitzgerald began coverage on shares of Hill-Rom Holdings in a research note on Thursday, June 29th. They issued a neutral rating and a $86.00 target price on the stock. Finally, Needham & Company LLC began coverage on shares of Hill-Rom Holdings in a research report on Thursday, June 29th. They set a buy rating and a $95.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Hill-Rom Holdings has a consensus rating of Buy and an average target price of $88.50.
Shares of Hill-Rom Holdings (NYSE HRC) traded down 1.08% on Tuesday, reaching $83.26. 433,228 shares of the company’s stock traded hands. The company’s 50-day moving average price is $77.56 and its 200 day moving average price is $68.18. Hill-Rom Holdings has a one year low of $49.90 and a one year high of $84.65. The firm has a market cap of $5.48 billion, a P/E ratio of 35.97 and a beta of 1.23.
Hill-Rom Holdings (NYSE:HRC) last posted its earnings results on Friday, April 28th. The medical technology company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Hill-Rom Holdings had a net margin of 5.80% and a return on equity of 19.77%. The business had revenue of $678.90 million for the quarter, compared to analysts’ expectations of $654.27 million. During the same period in the prior year, the company posted $0.71 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, equities analysts forecast that Hill-Rom Holdings will post $3.86 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/07/17/hill-rom-holdings-inc-nysehrc-downgraded-by-zacks-investment-research-to-hold.html.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 16th were issued a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Wednesday, June 14th. Hill-Rom Holdings’s dividend payout ratio is currently 31.03%.
In other news, SVP Andreas G. Frank sold 10,660 shares of Hill-Rom Holdings stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total transaction of $838,089.20. Following the sale, the senior vice president now owns 28,988 shares of the company’s stock, valued at approximately $2,279,036.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paul Sherwood Johnson sold 2,078 shares of Hill-Rom Holdings stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $72.30, for a total transaction of $150,239.40. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new position in shares of Hill-Rom Holdings during the fourth quarter valued at about $2,146,000. GSA Capital Partners LLP bought a new position in Hill-Rom Holdings during the fourth quarter valued at $235,000. Guggenheim Capital LLC boosted its position in Hill-Rom Holdings by 25.8% in the fourth quarter. Guggenheim Capital LLC now owns 52,379 shares of the medical technology company’s stock valued at $2,940,000 after buying an additional 10,738 shares during the last quarter. Norges Bank bought a new position in Hill-Rom Holdings during the fourth quarter valued at $36,707,000. Finally, Highbridge Capital Management LLC boosted its position in Hill-Rom Holdings by 92.9% in the fourth quarter. Highbridge Capital Management LLC now owns 422,467 shares of the medical technology company’s stock valued at $23,716,000 after buying an additional 203,502 shares during the last quarter. 83.86% of the stock is currently owned by hedge funds and other institutional investors.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Hill-Rom Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hill-Rom Holdings Inc and related companies.